BR0204465A - Metal center based nitric oxide donors - Google Patents

Metal center based nitric oxide donors

Info

Publication number
BR0204465A
BR0204465A BR0204465-0A BR0204465A BR0204465A BR 0204465 A BR0204465 A BR 0204465A BR 0204465 A BR0204465 A BR 0204465A BR 0204465 A BR0204465 A BR 0204465A
Authority
BR
Brazil
Prior art keywords
nitric oxide
oxide donors
metal center
center based
based nitric
Prior art date
Application number
BR0204465-0A
Other languages
Portuguese (pt)
Inventor
Luigi Casella
Marina Ziche
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Publication of BR0204465A publication Critical patent/BR0204465A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic System without C-Metal linkages

Abstract

"DOADORES DE óXIDO NìTRICO BASEADOS EM CENTROS METáLICOS". A invenção refere-se a complexos de ligando caracterizados pela presença de um resíduo piperazinaNONOato com cátions de metal em que os cátions derivam de um metal de transição ou de zinco em um estado de oxidação estável. Estes complexos são doadores de óxido nítrico e exercem um efeito endotélio-protetor sobre a região das coronárias e estimula os processos de reendotelialização e de angiogênese. A invenção compreende um processo de preparação e o uso terapêutico dos ditos compostos."NITRIC OXIDE DONORS BASED ON METALLIC CENTERS". The invention relates to ligand complexes characterized by the presence of a metal cation piperazine NONOate residue wherein the cations are derived from a transition metal or zinc in a stable oxidation state. These complexes are nitric oxide donors and exert an endothelium-protective effect on the coronary region and stimulate the reendothelialization and angiogenesis processes. The invention comprises a process of preparation and therapeutic use of said compounds.

BR0204465-0A 2001-03-01 2002-02-21 Metal center based nitric oxide donors BR0204465A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000426A ITMI20010426A1 (en) 2001-03-01 2001-03-01 NITROGEN OXIDE DONORS BASED ON METAL CENTERS
PCT/EP2002/001839 WO2002070496A1 (en) 2001-03-01 2002-02-21 Nitric oxide donors based on metallic centres

Publications (1)

Publication Number Publication Date
BR0204465A true BR0204465A (en) 2003-06-24

Family

ID=11447080

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0204465-0A BR0204465A (en) 2001-03-01 2002-02-21 Metal center based nitric oxide donors

Country Status (13)

Country Link
US (1) US6897218B2 (en)
EP (1) EP1370544B1 (en)
JP (1) JP2004518757A (en)
CN (1) CN1234698C (en)
AT (1) ATE322488T1 (en)
BR (1) BR0204465A (en)
DE (1) DE60210428T2 (en)
ES (1) ES2257538T3 (en)
HU (1) HUP0302262A2 (en)
IL (1) IL152555A0 (en)
IT (1) ITMI20010426A1 (en)
NO (1) NO324365B1 (en)
WO (1) WO2002070496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US7531505B2 (en) * 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
WO2007110084A1 (en) * 2006-03-27 2007-10-04 Salah Fathi Hussein Pyrazinic acid copper (i) complex
WO2010009739A1 (en) * 2008-07-22 2010-01-28 Ibraheim Salah Fathiy Hussein Copper(i)chloride complex of nicotinic acid and pharmaceutical compositions containing the same.
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
BR112012003792B1 (en) 2009-08-21 2020-05-19 Novan Inc topical composition, and, use of topical composition
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CN112266396B (en) * 2020-10-10 2021-08-20 中国药科大学 Integrated prodrug based on bio-orthogonal chemistry, preparation method and medical application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721365A (en) 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5389675A (en) 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors

Also Published As

Publication number Publication date
DE60210428D1 (en) 2006-05-18
NO20025223L (en) 2002-12-27
WO2002070496A1 (en) 2002-09-12
IL152555A0 (en) 2003-05-29
EP1370544B1 (en) 2006-04-05
DE60210428T2 (en) 2006-11-23
ATE322488T1 (en) 2006-04-15
HUP0302262A2 (en) 2003-10-28
ES2257538T3 (en) 2006-08-01
ITMI20010426A1 (en) 2002-09-01
CN1458926A (en) 2003-11-26
CN1234698C (en) 2006-01-04
US20040029854A1 (en) 2004-02-12
NO20025223D0 (en) 2002-10-31
JP2004518757A (en) 2004-06-24
US6897218B2 (en) 2005-05-24
EP1370544A1 (en) 2003-12-17
NO324365B1 (en) 2007-10-01

Similar Documents

Publication Publication Date Title
BR9909730A (en) Dihydropyrimidines
ES2060002T3 (en) CHELATE FORMING COMPOUNDS FOR THE COMPLEXATION OF RADIOACTIVE ISOTOPES, THEIR COMPLEXES WITH METALS, AS WELL AS THEIR USE IN DIAGNOSIS AND THERAPY.
BR0204465A (en) Metal center based nitric oxide donors
FR2417537A1 (en) COMPOSITION BASED ON HAFNIUM TO INHIBIT CORROSION OF METALS
TNSN99006A1 (en) 4- (2-CETO-1-BENZIMIDAZOLINYL) NOVEL PIPERIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR9913890A (en) Composition of oral care, and, use of complexes of copper, zinc, iron or divalent tin or trivalent iron, linked to a cyclic alpha-hydroxy ketone
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
BR0010688A (en) Surface-modified mixed oxides containing noble metal and titanium for selective hydrocarbon oxidation
BR8701981A (en) CERIO IV COMPOUND, PREPARATION PROCESSES FOR THIS COMPOUND AND A WATER SUN AND AQUEOUS SUN SO OBTAINED
DE3778869D1 (en) CORROSION INHIBITATION OF IRON METALS.
DK543987A (en) QUINOL-BASED COMPOUND, METHOD OF PREPARING IT, AND ANTICANCER COMPREHENSIVE SAME
KR960013376A (en) Anemia treatment containing iron and difructose
FR2434870A1 (en) YELLOW GOLD-BASED ALLOY THAT CAN BE USED IN PARTICULAR AS A DENTAL ALLOY WHICH MAY BE COATED WITH A CERAMIC MATERIAL
MA26726A1 (en) PHARMACEUTICAL COMPOSITION OF RESORCINOL, AND PROCESS FOR ITS PREPARATION
ATE53039T1 (en) TECHNETIUM AREN COMPLEXES AND PROCESSES.
FR2377805A1 (en) NEW COMPOSITION ESPECIALLY FOR THE TREATMENT OF CELLULITE
DE3773438D1 (en) IN 4-POSITION WITH NITROGEN SUBSTITUTED ISOCHINOLINOL COMPOUNDS WITH CARDIOTONIC PROPERTIES INHIBITING AND / OR RENAL VASODILATING PROPERTIES.
FR2634120B1 (en) NEW COSMETIC COMPOSITIONS BASED ON CHROMONE-CARBOXYLATES
ATE130304T1 (en) NEW ALPHA-GLUCOSIDASINE INHIBITORS.
DE3865683D1 (en) AQUEOUS CORROSION INHIBITING COMPOSITIONS CONTAINING DIPHENOLAMINE COMPOUNDS AS METAL CHELING AGENTS.
IT1150759B (en) ORGANOMETALLIC COMPLEXES OF N-CYCLOHEXY-PIPERAZINO-ACETAMIDES OR PROPIONAMIDS, THEIR PREPARATION AND USE AS ANTI-ULCER-ANTISECRETIVE-DAMPING DRUGS
CA2305764A1 (en) Bile acid salts of metals with physiological action and the use thereof in therapy
NO903111L (en) PROCEDURE FOR THE MANUFACTURE OF ANTI-INFECTIVE AGENTS.
Rudzitis Application of N, N'-Diphenylguanidine and Diantipyrylmethane Group Reagents for Extraction of Metal Ions
DE69012687T2 (en) Metal protective compositions, their manufacturing process and metal protection process.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.